



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Pharmacology and Therapeutics*

**Manuscript NO:** 74623

**Title:** Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 00006518

**Position:** Editorial Board

**Academic degree:** MD, MHSc, PhD

**Professional title:** Associate Professor, Chief Doctor, Doctor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** Australia

**Manuscript submission date:** 2023-04-02

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-04-03 00:19

**Reviewer performed review:** 2023-04-06 06:32

**Review time:** 3 Days and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

The authors treated three non-cirrhotic, antiviral treatment-naïve genotype 1a, 1b, and 3a chronic hepatitis C (CHC) patients with seizure disorders using glecaprevir-pibrentasvir 12 weeks with a dose-separated strategy from carbamazepine and achieved sustained virologic response 12 weeks after cessation of treatment (SVR12). They concluded that glecaprevir-pibrentasvir 12-week course was able to overcome reduced DAA plasma concentrations resulting from carbamazepine-related CYP 3A4 and P-gp induction. This manuscript is interesting and the information was not common in the literature; however, the language required further polish before considering for publication in its current edition.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Pharmacology and Therapeutics*

**Manuscript NO:** 74623

**Title:** Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03022180

**Position:** Editorial Board

**Academic degree:** FAASLD, MD, PhD

**Professional title:** Associate Professor, Professor

**Reviewer's Country/Territory:** Brazil

**Author's Country/Territory:** Australia

**Manuscript submission date:** 2023-04-02

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-04-02 18:58

**Reviewer performed review:** 2023-04-20 05:46

**Review time:** 17 Days and 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input type="checkbox"/> ] Anonymous [ <input checked="" type="checkbox"/> ] Onymous
	Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

### **SPECIFIC COMMENTS TO AUTHORS**

This case report may be helpful to daily prescribers of DAA to HCV- infected patients. Although it is already known that GP has only a potential interaction with carbamazepine the results regarding safety, in this case, a report deserves to be described.